Kaliki Swathi, Ayyar Anuradha, Nair Akshay G, Mishra Dilip K, Reddy Vijay Anand P, Naik Milind N
*Institute for Eye Cancer; and †Ophthalmic Pathology Service, L V Prasad Eye Institute, Hyderabad, India.
Ophthalmic Plast Reconstr Surg. 2016 Jan-Feb;32(1):35-9. doi: 10.1097/IOP.0000000000000398.
To report the efficacy of neoadjuvant systemic chemotherapy in the management of eyelid sebaceous gland carcinoma (SGC).
Retrospective study of 10 patients that received neoadjuvant systemic chemotherapy (Cisplatin/Carboplatin and 5-Fluorouracil) for eyelid SGC.
The mean age at presentation of eyelid SGC was 58 years (median, 55 years; range, 45 to 72 years). There were 6 females and 4 males. The mean tumor basal diameter was 36 mm (median, 31 mm, range, 20 to 65 mm), with orbital tumor extension in 9 cases. On the basis of TNM Classification, the tumors were classified as T3 (n = 10), N1 (n = 6), and M1 (n = 2). The mean number of cycles of neoadjuvant systemic chemotherapy per patient was 3 (median, 3; range, 3 to 4). The mean percentage reduction of tumor basal diameter after neoadjuvant chemotherapy was 74% (median, 80%; range, 30% to 100%). None of them had any major systemic side-effects of neoadjuvant chemotherapy. Postchemotherapy, surgical treatment for residual tumor was performed in 7 cases. Five cases underwent excision biopsy and 2 cases with residual orbital component underwent eyelid-sparing orbital exenteration. No tumor recurrence was noted in any of the 7 cases at a mean follow-up period of 18 months (median, 14 months; range, 3 to 63 months). One patient died due to systemic metastasis.
Neoadjuvant systemic chemotherapy is effective and safe in the management of eyelid sebaceous gland carcinoma.
报告新辅助全身化疗在眼睑皮脂腺癌（SGC）治疗中的疗效。
对10例接受新辅助全身化疗（顺铂/卡铂和5-氟尿嘧啶）治疗眼睑SGC的患者进行回顾性研究。
眼睑SGC患者的平均就诊年龄为58岁（中位数为55岁；范围为45至72岁）。其中女性6例，男性4例。肿瘤平均基底直径为36 mm（中位数为31 mm，范围为20至65 mm），9例有眶内肿瘤侵犯。根据TNM分类，肿瘤分为T3（n = 10）、N1（n = 6）和M1（n = 2）。每位患者新辅助全身化疗的平均周期数为3（中位数为3；范围为3至4）。新辅助化疗后肿瘤基底直径的平均缩小百分比为74%（中位数为80%；范围为30%至100%）。他们均未出现新辅助化疗的任何严重全身副作用。化疗后，7例患者对残留肿瘤进行了手术治疗。5例行切除活检，2例残留眶内成分者行保留眼睑的眶内容剜除术。7例患者平均随访18个月（中位数为14个月；范围为3至63个月），均未发现肿瘤复发。1例患者因全身转移死亡。
新辅助全身化疗治疗眼睑皮脂腺癌有效且安全。
